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ABSTRACT 
The present study is an attempt to develop bilayer matrix tablets of Nebivolol Hydrochloride and Valsartan with immediate release for 
Nebivolol Hydrochloride and sustained release for Valsartan. Superdisintegrants such as sodium starch glycolate and Crosscarmellose sodium 
were evaluated for immediate release of Nebivolol Hydrochloride and polymers HPMC K100M and K4M for sustained release of Valsartan. 
Preformulation studies were performed prior to compression. The compressed bilayer tablets were evaluated for weight variation, thickness, 
hardness, friability, drug content and in vitro drug release using USP dissolution apparatus type 2 in 0.01N HCl and phosphate buffer pH 6.8. All 
the pre and post compression parameters were found to be within the acceptable limits. The results of dissolution show that the formulations 
B3 was the best of all immediate and sustained release layer batches. The release kinetics of Valsartan was subject to curve fitting analysis in 
order to identify the best fit kinetic model. The regression analysis proves that the best formulations follow zero order release and drug release 
by diffusion process based on Fick’s law of diffusion. The data for stability studies infer no considerable change in drug co ntent and dissolution 
rates as per ICH guidelines. The best formulation B3 was subjected to in vivo pharmacokinetic studies in rabbit model. In vitro, In vivo 
correlation (IVIVC) showed considerable linearity. Hence a novel bilayer tablet formulation of Nebivolol Hydrochloride and Valsartan was 
successfully developed by combining both immediate (IR) and sustained (SR) release layers.  
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INTRODUCTION 
Developing a new molecule is expensive and time 
consuming. Other alternative .other alternative methods 
such as individualizing drug therapy, dose titrations, 
therapeutic drug monitoring and novel drug delivery system, 
using old drug by improving safety and efficacy ratio, brings 
out promising results. Successes in drug delivery research 
are the result of concerned efforts by the scientist of variety 
of disciplines who recognize the need and potentiate for 
improving pharmcotherapeutics through the development of 
novel drug delivery systems.  
The drug delivery systems are usually known by terms like 
sustained, controlled, targeted, smart, intelligent, novel, 
therapeutics and programmed. However the basic rationale 
for these varied delivery modules is the alteration or 
manipulation of the pharmacokinetic and pharmaco-
dynamics of pharmacologically active moieties. This can be 
achieved through novel drug delivery devices.1 
 Essential or primary hypertension is a persistent elevation 
of blood pressure which is not caused by underlying cardiac, 
endocrine or renal diseases.2 Approximately 70% of blood 
pressure elevations in youth represent early onset of 
essential hypertension.2,3 Attaining a target blood pressure 
can be very difficult with monotherapy especially in case of 
patients with multiple drug therapy. A survey on trends in 
the use of antihypertensive agents in France from 2002 to 
2012 supported the view of suboptimal treatment for 
hypertension with monotherapy and hence prescriptions of 
fixed dose combinations from 19% to 30%.3  
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Fixed dose combination refers to the combination of two or 
more active ingredients in a single pharmaceutical 
formulation.4 A number of clinical trials show that most 
hypertensive patients were unlikely to achieve a normal 
pressure by taking single drug for a quite a long time.5  
Formulation technologies such as multilayer tablets, 
multiparticulate systems, active film coating and hot melt 
granulation are developed in the design of formulation. 
Reviews of physicians’ desk reference show that infectious, 
cardiovascular, hormones, allergies and pain are the top 
most five medical areas for fixed dose combinations 0f oral 
dosage forms, nevertheless  hypertension treatment takes 
80% in cardiovascular.6 
Rationale for drug selection 
Valsartan is an angiotensin II receptor antagonist that is used 
in the treatment of hypertension. It act by blocking the 
binding of angiotensin II and I to its receptors thereby 
blocking vasoconstrictor and aldosterone secreting effect of 
angiotensin II selectively. The most preferred route for this 
drug is oral delivery in the form of tablets. Valsartan has 
poor water solubility, low bioavailability (approximately 20-
25%) and short half-life (nearly hrs.) which makes it an ideal 
candidate for sustained release. Hence in the present work 
this ideology is adopted.7 
Nebivolol is a novel beta1-blocker with a greater degree of 
selectivity for beta1- adrenergic receptors than other agents 
in this class and a nitric oxide (NO)-potentiating, 
vasodilatory effect that is unique among beta-blockers 
currently available to clinicians .A NO-potentiating agent 
such as Nebivolol may have an important role in 
hypertensive populations with reduced endothelial function 
such as diabetics, Nebivolol is unique among beta blockers in 
that, at doses <10 mg, it does not inhibit the increase in heart 
rate normally seen with exercise. The efficacy of Nebivolol 
has been tested successfully in clinical trials against other 
agents including other beta-blockers, angiotensin-converting 
enzyme-inhibitors and calcium channel antagonists in 
patients with hypertension, angina, and congestive heart 
failure. The tolerability of Nebivolol has been shown to be 
superior to that of atenolol and Metoprolol.8 
Multilayer tablets give a successful development of 
controlled release formulation and provide a way of 
successful drug delivery system. Conventional dosage form 
sometimes leads to undesirable toxicity and poor efficiency 
due to fluctuation in concentration in blood tissues.   
For the current research Nebivolol Hydrochloride in 
immediate release and Valsartan in sustained release layer 
was selected as fixed dose combination for bilayer tablet 
technology. Recently, fixed dose combination of Nebivolol 
hydrochloride, a selective β1 antagonist and valsartan an 
angiotensin II receptor blocker was approved by USFDA for 
hypertension. Pharmacological profiles of Nebivolol 
hydrochloride and valsartan alone and in combination are 
well characterized. In addition, a large 8-week randomized 
trial in stages I–II hypertensive patients (N=4161) 
demonstrated greater blood pressure-reducing efficacy for 
33Neb/valsartan SPCs than component monotherapies with 
comparable tolerability. In a biomarkers sub study (N=805), 
Nebivolol/valsartan single-pill combination prevented 
valsartan-induced increases in plasma renin, and a greater 
reduction in plasma aldosterone was observed with the 
highest single-pill combination dose vs. valsartan 320 
mg/day. 9 
MATERIALS AND METHODS  
Nebivolol hydrochloride and Valsartan were received as gift 
samples from Apotex Pharmachem India Pvt. Ltd. The 
polymers such as Hydroxypropyl Methylcellulose 
K100M(Methocel K100M premium), K4M(Methocel K4M 
premium), Dibasic calcium Phosphate(anhydrous, FCC), 
Sodium Starch Glycolate(731713H),Croscarmellose 
sodium(Ac di sol NF), FD&C blue lake, microcrystalline 
cellulose, silicon dioxide(Aerosil 200) and magnesium 
stearate(ligamed MF) were obtained from KMS Pharma - 
Formulation development Healthcare Pvt Ltd.  
Formulation of Bi-layer tablets: 
The ingredients after sifting, Prelubrication and blending 
was subjected for precompression parameters like excipient 
compatibility studies (Table 1, 2), Angle of Repose, Bulk 
Density, Tapped Density Carr’s. Index (%), Hausner’s Ratio.10 
the results are shown in table 3and 4. The FTIR studies were 
done for standard Nebivolol HCl, Valsartan and Excipients. 
 
 
Figure 1: IR spectrum of Valsartan 
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Figure 2: IR spectrum of Valsartan and SR excipients 
 
 
Figure 3: IR spectrum of Nebivolol 
 
 
Figure 4: IR spectrum of Nebivolol and IR excipients 
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Table 1: Excipient compatibility studies for Valsartan 
 
 
Table 2: Excipient compatibility studies for Nebivolol Hydrochloride 
 
Table 3: Pre-compression Parameters of Nebivolol hydrochloride 
Formulation Angle of 
Repose* 
Bulk Density* Tapped Density* Carr’s. Index 
(%)* 
Hausner’s 
Ratio* 
B1 280.46’±0.26 0.6130±0.0071 0.799±0.0021 23.28±0.71 1.304±0.008 
B2 280.46’±0.35 0.613±0.0071 0.799±0.0024 23.28±0.75 1.304±0.007 
B3 280.46’±0.72 0.613±0.091 0.799v0.0019 23.28±0.80 1.304±0.098 
B4 270.23’±0.27 0.597±0.0091 0.789±0.0030 23.94±0.69 1.315±0.009 
B5 270.23’±0.34 0.597±0.0092 0.789±0.0023 23.94±0.73 1.315±0.089 
B6 270.23’±0.70 0.597±0.0074 0.789±0.0018 23.94±0.79 1.315±0.097 
Where, *All values are mean ± SD, n=3, 
 
 
 
S.N. Drug+ Excipients Ratio 
 
Initial 
 
Condition 
400C/75%RH 
7 days 14 days 30 days Conclusion 
1. 
Valsartan  + Microcrystalline cellulose 
(Avicel PH 102) 
1:1 
A white 
or almost 
white 
crystalline 
powder 
No 
change 
No change No change compatible 
2. Valsartan + Dibasic calcium Phosphate 1:1  
No 
change 
No change No change compatible 
3. 
Valsartan +Hydroxy Propyl Methyl 
Cellulose  (Metolose 90SH 4000SR) 
1:1 
No 
change 
No change No change compatible 
4. 
Valsartan + Hydroxy Propyl Methyl 
Cellulose  (HPMC K100M) 
1:1 
No 
change 
No change No change compatible 
5. 
Valsartan + Colloidal silicon Dioxide 
(Aerosil-200) 
1:0.25 
No 
change 
No change No change compatible 
6. Valsartan + Magnesium Stearate 1:0.25 
No 
change 
No change No change compatible 
S.N. Drug+ Excipients Ratio 
Initial 
 
Condition 
400C/75%RH 
7 days 14 days 30 days Conclusion 
1. 
Nebivolol Hydrochloride + Dibasic 
calcium Phosphate 
1:1 
A white or 
almost white 
crystalline 
powder 
No 
change 
No 
change 
No 
change 
Compatible 
2. 
Nebivolol Hydrochloride + 
Microcrystalline Cellulose (Avicel PH 
102) 
1:1 
No 
change 
No 
change 
No 
change 
Compatible 
3 
Nebivolol Hydrochloride  +  Sodium 
Starch Glycolate 
1:1 
No 
change 
No 
change 
No 
change 
Compatible 
4 
Nebivolol Hydrochloride +  
Croscarmellose  sodium 
1:1 
No 
change 
No 
change 
No 
change 
Compatible 
5 
Nebivolol Hydrochloride +  Hydroxy 
Propyl Methyl Cellulose ( HPMC 
K100M) 
1:10 
No 
change 
No 
change 
No 
change 
Compatible 
6 
Nebivolol Hydrochloride  +  Hydroxy 
Propyl Methyl Cellulose (Metolose 
90SH 4000SR) 
1:10 
No 
change 
No 
change 
No 
change 
Compatible 
7 
Nebivolol Hydrochloride +  Colloidal 
silicon Dioxide (Aerosil-200) 
1:0.25 
No 
change 
No 
change 
No 
change 
Compatible 
8 
Nebivolol Hydrochloride + 
Magnesium Stearate 
1:0.25 
No 
change 
No 
change 
No 
change 
Compatible 
9 
Nebivolol Hydrochloride + FD&C 
blueLake 
1:0.25 
A yellow  
crystalline 
powder    
No 
change 
No 
change 
No 
change 
Compatible 
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Table 4: Pre-compression Parameters of Valsartan 
Formulation Angle of Repose* Bulk Density* Tapped Density* C. Index (%)* Hausner’s Ratio* 
B1 270.28’±0.27 0.329±0.0094 0.5280±0.0019 37.73±0.77 1.606±0.007 
B2 280.10’±0.71 0.335±0.0075 0.533±0.0025 37.25±0.74 1.594±0.006 
B3 280.35’±0.77 0.305±0.008 0.536±0.0028 38.137±0.81 1.759±0.097 
B4 280.32’±0.49 0.350±0.009 0.534±0.0026 34.42±0.79 1.525±0.078 
B5 280.36’±0.25 0.333±0.0069 0.522±0.0024 36.26±0.82 1.569±0.008 
B6 280.56’±0.78 0.306±0.0077 0.486±0.0029 36.98±0.74 1.587±0.087 
Where, *All values are mean ± SD, n=3, 
 
Six formulations of bilayer tablets were prepared with the 
variation of excipients as mentioned Table No 5. Various 
steps (Sifting, Dry mixing, Prelubrication and Lubrication) 
involved in direct compression process.11 the compressed 
tablets were analyzed for post compression parameters. The 
details of the results are shown in table no 6.  
Preparation of Nebivolol Hydrochloride immediate release 
(IR) layer: 
The active Ingredient Nebivolol hydrochloride and diluents 
Micro crystalline cellulose (Avicel PH 102), Dibasic calcium 
Phosphate (anhydrous, FCC), were sifted through 40 mesh 
sieve. Sodium Starch Glycolate(731713H), Croscarmellose 
sodium (Ac di sol NF),were sifted through 60 mesh sieve. 
FD&C blue lake, was sifted through 100 mesh sieve. 
Dry mixing: Mix geometrically Nebivolol hydrochloride with 
Micro crystalline cellulose (Avicel pH 102), Dibasic calcium 
Phosphate, Disintegrants (SSG or CCS) and FD&C blue lake, 
were taken in a poly bag and mixed for 15minutes to ensure 
uniform mixing of the ingredients with the drug.   
Preparation of Valsartan sustained release (SR) layer:  
The active ingredient Valsartan, was passed through the 40 
mesh sieve followed by the other ingredients were passed 
the same sieve. 
Dry mixing: Valsartan, Polymer [Hydroxypropyl 
Methylcellulose K100M (Methocel K100M premium), K4M 
(Methocel K4M premium)] diluents [Dibasic calcium 
Phosphate (anhydrous, FCC)] were taken in a planetary 
mixer and mixed for 15 minutes to ensure uniform mixing of 
the ingredients with the drug. 
Prelubrication: Colloidal slicondioxide (Aerosil-200), sifted 
through 40 mesh sieve were mixed with dry mixed blend for 
5 minutes. 
Lubrication and compression of Bilayer tablets: 
Magnesium stearate, was weighed and were passed through 
60 mesh sieve. Then mixed with dried granules of Valsartan 
and Nebivolol Hydrochloride separately in a polybag for 
5minutes to get a uniform blend. Then the lubricated 
granules of Valsartan and Nebivolol Hydrochloride were 
added in the separate hopper in double rotary punching 
machine and compressed into Bilayer tablets using 
13.5X.7.5mm oblong shape punches, at target weight of 300 
mg. 
The stock standard solution of Nebivolol and Valsartan were 
prepared by dissolving accurate amount of the drugs initially 
in methanol and diluted with 6.8 ph. phosphate buffer to get 
the first stock solution. From this stock solution series of 
dilutions were made to get a concentration range of 5-100 
ppm. A linearity graph was obtained by measuring the 
absorbance of the series of dilution of the drugs at 281 nm 
and 251 nm for Nebivolol hydrochloride and valsartan 
respectively. 
 
 
 
Figure 5: Linearity of Nebivolol Hydrochloride and Valsartan 
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Table 5: Composition of Nebivolol Hydrochloride and Valsartan in IR layer and SR layer 
  
The compressed tablets were evaluated for weight variation, content uniformity, hardness, thickness and drug content8. The 
results are shown in table no 6 
Table 6:  Physical characterizations of Bi-layer tablets. 
Batch 
code 
Avg. Wt. (mg) 
Hardness*(kg/c
m2 ) 
Thickness *mm 
Drug content (%)* 
Friability (%) 
Nebivolol valsartan 
B1 304.3±1.24 17.3±4.31 3.91±2.31 91.27 95.65 0.58±2.36 
B2 296.0±2.72 15.93±5.21 3.89±2.35 90.75 95.49 0.56±4.21 
B3 306.2±4.24 17.34±6.32 3.91±3.52 91.27 95.65 0.54±1.23 
B4 303.2±3.21 18.67±3.5 3.92±4.12 91.27 95.65 0.58±4.21 
B5 302.9±1.52 17.77±2.31 3.91±4.36 90.75 95.65 0.55±2.36 
B6 304.2±3.23 12.64±4.21 4.13±2.42 91.27 95.49 0.56±4.25 
Where, *All values are mean ± SD, n=3,  
In vitro dissolution study 12 
The in vitro dissolution of Nebivolol Hydrochloride and 
Valsartan bilayer tablets were determined using USP XXIII 
(basket method) dissolution apparatus. The basket was 
allowed to rotate at a speed of 50 rpm and temperature of 37 
± 0.5°C was maintained. The dissolution medium used was 
900 ml of 0.1N HCl (pH 1.2) for the initial 2hours followed by 
study in simulated intestinal fluid Phosphate buffer solution 
(pH 6.8). Aliquots (5 ml) of sample were collected at 
predetermined time intervals (1, 4, 8, 20, 24 hrs.) from the 
dissolution apparatus and it was replaced with equal volume 
of fresh dissolution medium. The aliquots withdrawn were 
filtered through 0.45µm millipore filters. The concentration 
of both the drugs in the dissolution media was estimated by 
UV spectrophotometric method at 281 nm and 251nm for 
Nebivolol hydrochloride and Valsartan respectively.  
  
Nebivolol Hydrochloride and Valsartan Bilayer tablets 
Formulation Plan 
S.
N. 
Ingredients 
B1 B2 B3 B4 B5 B6 
mg/T
ab 
%W/
W 
mg/T
ab 
%W/
W 
mg/T
ab 
%W/
W 
mg/T
ab 
%W/
W 
mg/T
ab 
%W/
W 
mg/T
ab 
%W/
W 
First layer 
1 
Nebivolol 
Hydrochloride 
5 5 5 5 5 5 5 5 5 5 5 5 
2 
Microcrystalline 
cellulose (Avicel PH 
102) 
37.95 37.95 32.95 32.95 34.95 34.95 34.95 34.95 32.95 32.95 37.95 37.95 
3 
Dibasic calcium 
Phosphate 
51.8 51.8 51.8 51.8 51.8 51.8 51.8 51.8 51.8 51.8 51.8 51.8 
4 
Sodium starch 
Glycolate 
4 4 4 4 4 4 0 0 0 0 0 0 
5 
Croscarmellose 
sodium 
0 0 0 0 0 0 4 4 4 4 4 4 
6 FD&C blue lake 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25 
7 Mg. Stearate 1 1 1 1 1 1 1 1 1 1 1 1 
Total 100 100 100 100 100 100 100 100 100 100 100 100 
Second layer 
8 valsartan 60 23.75 60 23.75 60 23.75 60 23.75 60 23.75 60 23.75 
9 
Microcrystalline 
cellulose (Avicel PH 
102) 
86 49.25 98 55.25 91 52.25 92 52.25 76 44.25 16 34.25 
10 HPMC K100M 50 25 38 19 44 22 0 0 0 0 0 0 
11 HPMC K4M 0 0 0 0 0 0 44 22 60 30 120 40 
12 Sio2 2 1 2 1 2 1 2 1 2 1 2 1 
13 Mg. Stearate 2 1 2 1 2 1 2 1 2 1 2 1 
Total 200 100 200 100 200 100 200 100 200 100 200 100 
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Table 7:  Dissolution parameters 
  Nebivolol Hydrochloride Valsartan 
Dissolution media 0.01N HCl pH 6.80 Phosphate Buffer 
Volume 900ml 900ml 
Model USP TYPE II Paddle  USP TYPE II Paddle 
Rpm 50 50 
Time of sampling 15,30Mins 1,4,8,20 Hrs 
Temperature 370 c 370 c 
 
Table 8: Drug Release from Valsartan sustained release (SR) layer 
 
B1* B2* B3* B4* B5* B6* 
Time Hrs %CDR %CDR %CDR %CDR %CDR %CDR 
0 0 0 0 0 0 0 
1 11±8.94 12±7.45 18±22.41 11±0.00 9±9.94 10±0.00 
4 25±11.50 25±6.20 30±1.36 27±2.03 24±16.81 24±6.46 
8 37±7.77 39±8.70 46±3.00 43±4.01 38±14.49 40±2.58 
20 64±5.17 66±5.91 80±5.92 79±8.50 70±13.66 72±0.57 
24 71±3.64 76±5.92 84±6.76 87±9.33 80±13.80 81±2.92 
Where,*All values are mean ± RSD, n=6. ,  
 
 
Figure 6: Drug Release from Valsartan SR layer for formulations B1 to B6 
Table 9: Drug Release from Nebivolol hydrochloride immediate release (SR) layer 
I set Dissolution of IR1 with SR1,SR,SR3 Time mins 
15 30 
B1* 65±3.94 79±7.36 
B2* 71±4.91 83±1.77 
B3* 79±6.72 92±3.47 
II set DIssolution of IR2with SR4,SR5,SR6  
B4* 71±5.49 83±6.17 
B5* 67±1.12 835.25 
B6* 74±22.31 81±4.73 
Where,*All values are mean ± RSD, n=6. , 
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Figure 7: Drug Release from Nebivolol Hydrochloride IR 
layer for formulations B1 to B3 
 
 
Figure 8: Drug Release from Nebivolol Hydrochloride IR 
layer for formulations B4 to B6
From the results of the evaluation formulation B3 was 
considered best formulation where the IR layer containing 
Nebivolol layer showing maximum release of 92 % in 30 min 
and SR layer containing Valsartan layer showing a slow and 
sustained release for a period of 24 hrs. B3 was subjected to 
curve fitting analysis to predict the pattern of drug release. 
  
Table 10: Release kinetics 
Model Zero order Higuchi 
Korsemeyer 
Peppas 
Hixon 
Crowell 
First order 
Correlation 
coefficient r 
0.9746495 0.9971163 0.8165266 0.058066 -0.894879 
 
Interpretation of the kinetic studies: 
 The r value for zero order release indicates the SR layer 
containing valsartan follows zero order release pattern 
where in the drug release at any moment is 
independent of the initial concentration.  
 The r value for Higuchi model infers the SR layer 
follows a drug release by diffusion process based on 
Fickian law of diffusion.  
 The r value for Peppas model shows no linearity.  
 The r value for Hixon Crowell value indicates no 
linearity and hence proves that the drug release from 
SR layer is not by dissolution. 
In vivo pharmacokinetic studies: 13 
An in vivo pharmacokinetic study was carried out according 
to ethical guidelines for investigations in laboratory animals 
and approved by the Institutional Animal Ethics Committee 
(IAEC) reference No. in vivo/041.All procedures and care of 
the rabbits were in accordance with institutional guidelines 
for animal use in research. Four healthy male albino rabbit 
weighing 2-2.5 were fasted overnight. Tablets were 
administered orally. Rabbits were held in rabbit restrainers 
during blood sampling. Blood samples were collected from 
marginal ear veins at predetermined intervals of 0, 0.5, 1, 2, 
3, 4, 6, 8, 20 and 24 h post dose into heparinized tubes. 
Plasma samples were obtained following centrifugation of 
blood and kept frozen at -20 degree until analysis until liquid 
chromatography/mass spectrometry (LC/MS-MS) analysis.
 
 
Table 11: Plasma concentration of Nebivolol Hydrochloride in rabbit plasma 
Animal 
code  1 2 3 4 avg conc  
time (hrs) conc ng/mL conc ng/mL conc ng/mL conc ng/mL ng/ml 
0 0 0 0 0 0 
0.5 72.1 32.9 18 22.5 36.4 
1 17.7 25.4 22.6 22.1 22 
2 14.7 19.4 24 23.6 20.4 
3 221 61.3 61 41.9 96.3 
4 31.6 72.4 34.1 35.9 43.5 
6 65.5 14.8 23.2 24.3 32 
8 18.4 30.1 49.2 34.1 33 
20 31.9 27.7 25.4 23.9 27.2 
24 20.1 23.4 40.1 18.5 25.5 
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Table 12: Plasma concentration of Valsartan in rabbit plasma 
Animal code 1 2 3 4 avg conc 
Time (hrs) conc ng/mL conc ng/mL conc ng/mL conc ng/mL conc ng/mL 
0 0 0 0 0 0 
0.5 12600 15600 6870 5020 10022.5 
1 8600 12200 3400 4190 7097.5 
2 15900 9980 1450 4980 8077.5 
3 17700 3100 3090 13400 9322.5 
4 12100 9970 26100 1570 6562.5 
6 19400 6770 2410 3760 8085 
8 1610 1210 4620 537 1994.3 
20 20500 24400 30400 34900 27550 
24 21100 24200 24300 21900 22875 
 
  
 
Figure 9: Bioavailability of Valsartan 
 
Figure 10: Bioavailability of Nebivolol Hydrochloride
Table 13: Details of LCMS analysis 
LC conditions 
Column ACE C18 PFP (150 x 4.6mm, 3µ particle size) 
Flow rate 1 ml/min 
Column oven Temp. 40°C 
Injection volume 10 µl 
Mobile phase A-----0.1% formic acid in water  
B-----Acetonitrile+0.1% formic acid 
A:B-gradient elution 
 
  
  
  
  
   
 Mins B.Conc. 
0.01 30% 
5.00 30% 
8.00 80% 
10.00 30% 
12.00 30% 
MS/MS conditions 
Source Electron spray ionization (ESI +&- mode) 
Source Temp. 420°C 
Curtain gas 30 psi 
Ion source gas (GS1) 50 psi 
Ion source gas (GS2) 60 psi 
Scan time 100 msec 
MRM details 
Name of the analyte Transition state CE (V) DP (V) FP (V) Ion source 
voltage 
Valsartan 434.0>179.0 -30V -60V -400V -3500V 
Nebivolol 406.1>151.0 40V 50V 400V 3500V 
Phenacetin (Internal standard) 180.05>110.05 30V 20V 400V 3500V 
CE=Collision Energy; DP: Declustering Potential; FP = Focusing Potential 
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An ionization was checked in both the ionization mode 
(Positive and negative mode) and it was observed that 
Valsartan was shown good ionization in negative mode 
(deprotonated) and Nebivolol and Phenacetin (IS) were 
given good intense response in positive ionization mode 
(protonated). 
Standard curve:    
A stock cocktail solution (containing Nebivolol and 
Valsartan) ranging from 1000 – 0.312 µg/ml was prepared 
using LC-MS grade methanol. Further this was diluted to 
obtain a working standard solution ranging from 25.9ng/ml 
to 83000ng/ml. The dilution was performed by pipetting 
33.2µL separately from each stock and making up the 
volume to 200µL using untreated plasma and mixed by 
vortex for 30 seconds. After 10 minutes of incubation, 10µL 
of (25ppm) Phenacetin (internal standard) was added and 
vortex for 30 seconds. 600µL of methanol was added to 
precipitate the proteins. The samples were subjected to 
centrifugation at 8000rpm for 5 minutes at 15ºC. The 
supernatant was separated and subjected to LC-MS/MS 
analysis. 
Procedure:            
To the assay vial, 200µl of rabbit plasma was added followed 
by addition of 10 µl of internal standard Phenacetin at the 
concentration of 25ppm. 600 µl of 0.1% formic acid in 
methanol was added to precipitate the plasma contents 
mixed by vortex for 30 seconds. The above samples were 
subjected to vortex for 30 seconds followed by centrifugation 
at 8000rpm for 5 minutes at 15°C. The supernatant was 
collected and subjected to LCMS analysis. The 
pharmacokinetic parameters were estimated using Phoenix 
WinNonlin® (Version 8.1, USA). 
 
Table 14: Pharmacokinetic parameters of Nebivolol Hydrochloride and valsartan in rabbits following single dose 
administration of Bilayer tablet 
  ANALYTE 
  Nebivolol Valsartan 
Animal ID Dose 
(mg) 
Tmax 
(hr) 
cmax 
ng/ml 
AUC last 
hr*ng/ml 
Tmax(hr) cmax 
ng/ml 
AUC last 
hr*ng/ml 
 
1 (5/60mg) 3 221 766.37 24 21000 313814.1 
2 (5/60mg) 4 72.4 693.44 20 24400 303544 
3 (5/60mg) 3 61 814.98 20 30400 369320.6 
4 (5/60mg) 3 41.9 637.24 20 34900 356605.2 
5 Mean 3.25 99.075 728.009 21 27700 335821.1 
6 SD 0.5 82.252 78.464 2 6153.048 32043.09 
7 SE 0.25 41.26 39.232 1 3076.524 16021.55 
8 CV% 15.4 83 10.8 9.5 22.2 9.5 
9 Min 3 41.9 637.24 20 21100 303544.5 
10 Median 3 66.7 729.91 20 27400 335209.7 
11 Max 4 221 814.98 24 34900 369320.6 
 
 
In vitro In vivo correlation (IVIVC) 
Recently, application of IVIVC has been suggested in the 
pharmaceutical field for development of novel formulations 
to reduce the time and cost of manufacturing.14The FDA has 
developed a regulatory guidance for both immediate and 
modified release dosage forms, thus minimizing the need for 
bioavailability studies as a part of the formulation design and 
optimization process. Among the poorly water soluble drugs, 
BCS class II drugs could be applied to IVIVC, since dissolution 
is the rate limiting step for drug absorption in gut.15 This 
concept holds good for Nebivolol Hydrochloride which 
belong to BCS class II, also an immediate release layer of this 
drug would further enhance the dissolution there by 
improving absorption. Though Valsartan belongs to BCS class 
IV, it behaves as BCS class III drug since it shows good 
solubility in intestinal Ph. hence can be considered for IVIVC. 
 
 
 
 
Table 15: IVIVC for Valsartan 
Time (hr) 
In-vivo 
Plasma conc ng/ml 
In-vitro 
%CDR 
0  0 0 
0.5 10022.5 -  
1 7097.5 18 
2 8077.5  - 
3 9322.5  - 
4 6562.5 30 
6 8085  - 
8 1994.3 46 
20 27550 80 
24 22875 84 
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Figure 11: IVIVC for Valsartan r= 0.852475 
Table 16: IVIVC for Nebivolol Hydrochloride 
Time (hr) 
Invivo 
Plasma conc 
ng/ml 
invitro 
%CDR 
0 0 0 
0.25 36.4 79 
0.5 22 92 
1 20.4  - 
2 96.3  - 
 
 
Figure 12: IVIVC of Nebivolol Hydrochloride r= 0.860495 
Stability studies 16 
In the present analysis, stability studies were carried out for 
both at room temperature and accelerated stability 
conditions. The conditions for storing at room temperature 
were kept as 30±2 °C and 65±5% RH and for accelerated 
stability conditions were kept at 40±2°C and 75±5% RH in a 
humidity chamber. At regular intervals of time (0, 2, 4 and 6 
months) samples were withdrawn and evaluated for drug 
content and in-vitro release profile. All the parameters were 
within the acceptable limits. 
RESULTS AND DISCUSSION 
Various formulations of Bilayer tablets were prepared and 
evaluated with an aim to develop Valsartan as sustained 
release layer and Nebivolol Hydrochloride as an immediate 
release layer for improving hypertension therapy of two 
drugs and also patient’s compliance. To minimize the critical 
process parameters, direct compression method was 
selected for the formulation. The polymers and other 
excipients were selected based on the satisfying results 
produced during Drug-Excipients compatibility studies to 
develop the final formulation (Table 1&2).  Results show the 
compatibility of drug with the excipients. The 
physicochemical evaluation results for the granules of all 
trials pass the official limits with respect bulk and tapped 
density, angle of repose, Carr’s index ans hausners’ ratio 
(Table 3). In present work a bulk density in the range of 0.5 -
0.6 gm/cm3indicates a good packing characteristics. The 
Carr’s compressibility index was found to be in the range of 
23 % which suggested optimal compressibility. The values of 
hausner ratio where found in the range of 1.30 suggested 
optimal flowability of powder blend. The angle of repose of 
all the blend was within range of 28 to 28 indicated excellent 
flow property of powder blend. The bilayer tablets were 
evaluated for different physical parameter. The hardness of 
bilayer tablet was found in the range of 12 to 17 kg/cm2 
which was more as compare to individual layer because of 
double compression. The thickness of the bilayer tablet was 
in the range of 3 – 4 mm which is an excellent value for 
double layer. The friability was 0.54 - 0.58% for bilayer 
tablet which was less than 1 indicating good handling of 
tablet. The weight variation study showed low standard 
deviation uniformity in weight of the tablets 300 ± 0.06mg.17 
In the formula of Nebivolol Hydrochlioride immediate 
release layer, super disintegrants sodium starch glycolate 
and Croscarmellose sodium were used 4 mg per tablet. The 
results of drug release from IR layer, infers that at the 
concentration of 4 mg both the super disintegrants comply 
with the limit for drug release in 30 min(Table:9, fig 4). In 
the formula for Valsartan sustained release layer, 
Hydroxypropyl Methyl Cellulose (HPMC K 100 M) and HPMC 
K 4M were used as retardant polymers. From the drug 
release profile it infers that Hydroxypropyl Methyl Cellulose 
(HPMC K 100 M) at a concentration of 50 t0 60% produced 
desired release profile for Valsartan extended release layer 
as per USP limits. B3 was considered the best formulation 
based on the release profile of both the drugs in immediate 
and sustained release layer. (Table: 10, fig 3&3A). To analyze 
the pattern of drug release, the drug release data of the best 
formulations were subject to release kinetics studies. (Table 
10) The results show that formulation B3 depicts zero order 
release pattern in which the prime mechanism is diffusion 
controlled release. B3 optimized tablets was selected for 
accelerated stability studies for a period of one month at 
40°C/75%R. as per in-house specifications. The stability 
studies confirmed that there was no significant difference 
over the testing period with respect to dissolution profile, 
assay and other physical parameters thus satisfying in-house 
specifications. In vivo pharmacokinetic studies in Rabbit 
animal model was carried out for best formulation B3.The 
pharmacokinetic parameters are summarized in table 11.  
CONCLUSION:  
From present study, it can be concluded that bilayer tablet 
dosage form is an ideal fixed dosage form for formulating 
combination of drugs. Bilayer tablet containing Nebivolol 
Hydrochloride and Valsartan in immediate release and 
sustained release layers respectively would be a novel 
concept in treating hypertension. I formulation point of view 
precompression and Post compression parameters suggests 
that, this formulae of drug and excipient combination would 
provide a satisfactory results. 
The immediate release layer of Nebivolol Hydrochloride 
helps in the immediate release of the drug which acts as 
loading dose to reduce hypertension initially. The modified 
release of Valsartan in Sustained release layer is helpful in 
maintaining the drug levels above the minimum required 
concentration for a long duration. This reduces dosing 
frequency from twice a day to once a day. Hence this 
technology can be used to formulate fixed dosage form of 
Nebivolol Hydrochloride and Valsartan which can give an 
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optimal therapy for hypertension. The IVIVC suggests a 
moderate linearity between the In vitro and In vivo results. 
These findings could be substantiated by further 
pharmacodynamic evaluation.  
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